AstraZeneca’s Calquence, a selective Bruton’s tyrosine kinase, or BTK, inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naive chronic lymphocytic leukaemia, or CLL. Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca’s Lynparza approved in E.U. as first line treatment in mCRPC
- Merck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU
- AstraZeneca’s Imfinzi+chemotherapy approved in E.U. in BTC patients
- AstraZeneca, G42 Healthcare enter strategic partnership agreement
- AstraZeneca says PEARL trial didn’t achieve statistical significance on endpoint
